Orchestra BioMed Holdings (OBIO) Profit After Tax (2021 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Profit After Tax of -$20.7 million for Q1 2026, down 10.32% year-over-year from -$23.1 million in Q1 2025, and down 430.53% quarter-over-quarter from $6.3 million in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Profit After Tax (2021 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Profit After Tax for 6 consecutive years, with -$20.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 10.32% year-over-year to -$20.7 million; the TTM figure through Mar 2026 stood at -$54.6 million (up 17.66% YoY), while the FY2025 annual figure was -$52.7 million, up 13.65% from the prior year.
- Profit After Tax fell to -$20.7 million in Q1 2026 per OBIO's latest filing, from $6.3 million in the prior quarter.
- Across five years, Profit After Tax topped out at $6.3 million in Q4 2025 and bottomed at -$20.8 million in Q3 2025.
- Historically, Profit After Tax has averaged -$12.8 million across 5 years, with a median of -$13.3 million in 2023.
- Annual changes were most pronounced in 2022 — Profit After Tax sank 11272.51% — and 2025, when it jumped 138.49%.
- Orchestra BioMed Holdings' Profit After Tax stood at -$9.8 million in 2022, then sank by 31.47% to -$12.8 million in 2023, then retreated by 26.88% to -$16.3 million in 2024, then surged by 138.49% to $6.3 million in 2025, then plunged by 430.53% to -$20.7 million in 2026.
- Business Quant data shows OBIO's Profit After Tax at -$20.7 million in Q1 2026, $6.3 million in Q4 2025, and -$20.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Orchestra BioMed Holdings | 324.80 Mn | 130.27 Mn | 63,000.00 | -23.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -23.80 Mn |
| Mar 31, 2026 | -20.69 Mn |
| Dec 31, 2025 | 6.25 Mn |
| Sep 30, 2025 | -20.83 Mn |
| Jun 30, 2025 | -19.38 Mn |
| Mar 31, 2025 | -18.76 Mn |
| Dec 31, 2024 | -16.16 Mn |
| Sep 30, 2024 | -15.43 Mn |
| Jun 30, 2024 | -15.98 Mn |
| Mar 31, 2024 | -13.46 Mn |
| Dec 31, 2023 | -12.75 Mn |
| Sep 30, 2023 | -13.32 Mn |
| Jun 30, 2023 | -12.05 Mn |
| Mar 31, 2023 | -10.94 Mn |
| Dec 31, 2022 | -9.76 Mn |
| Sep 30, 2022 | -10.28 Mn |
| Jun 30, 2022 | -7.85 Mn |
| Mar 31, 2022 | -5.73 Mn |
| Dec 31, 2021 | -88,011.00 |
| Sep 30, 2021 | -90,411.00 |